Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

"After recent discussions with Health Authorities, we are excited to be initiating the first of a series of pivotal studies to explore an interferon-free regimen of PSI-7977 in broad populations of individuals with HCV," said Michael Rogers, Ph.D., Pharmasset's Chief Development Officer.

The first trial, FISSION, will enroll approximately 500 treatment-naive patients with HCV genotype 2 or 3, and will evaluate the safety and efficacy of a 12-week interferon-free regimen of PSI-7977 and ribavirin compared to 24 weeks of pegylated interferon and ribavirin. The primary endpoint of the study is sustained virologic response 12 weeks after the completion of treatment (SVR12).

Pharmasset plans to initiate a second 12-week duration, interferon-free Phase 3 trial, POSITRON, in early 2012. This trial will enroll approximately 225 patients with HCV genotype 2 or 3 who cannot take interferon.

In mid-2012, Pharmasset intends to initiate a third 12-week duration, interferon-free Phase 3 trial, NEUTRINO. This trial will enroll patients who cannot take interferon, and will include patients with HCV regardless of viral genotype, including those with HCV genotype 1. The final study design will be based on emerging data from ELECTRON and from PSI-7977 plus RBV-containing arms in the ongoing QUANTUM study.

"Based on encouraging results to date, we have selected an IFN-free regimen of PSI-7977/RBV for our registrational program," said Michelle Berrey, MD, MPH, Pharmasset's Chief
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2
... /PRNewswire-FirstCall/ --,Genta Incorporated announced the presentation of ... its marketed product, Ganite(R) (gallium,nitrate injection), plus ... relapsed or refractory non-Hodgkin's,lymphoma (NHL). The data ... American Society of Clinical Oncology (ASCO) in ...
... in 35% of HER2-Positive Metastatic Breast,Cancer ... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated presented data ... that alvespimycin, its second-generation Hsp90,inhibitor, demonstrated ... with trastuzumab (Herceptin(R)) in,patients with refractory ...
Cached Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... print component of Healthy Aging is distributed within today’s ... and an estimated readership of 420,000. The digital component ... and across a network of top news sites and ... campaign, click here . , The publication features ... The Social. Lainey Lui, Melissa Grelo, Traci Melchor, ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... Funding Suspension After Trial Failures, WASHINGTON, ... piece today ( http://www.baltimoresun.com/news/opinion/oped/bal -,op.aidsvaccine23mar23,0,3426636.story), AIDS Healthcare ... HIV vaccine research funding and the,re- allocation ... and treatment strategies., Co-authored by Dr. ...
... can shield children from harm , , SATURDAY, March 22 ... which concludes Saturday, the Soap and Detergent Association offers ... , Parents and caregivers should: , Install child-safety ... chemicals and other poisons. Never assume a cabinet is ...
... But it,s not too late to protect yourself and ... News) -- News from the diabetes front seems to ... the disease, fueled by obesity and sedentary lifestyles, have ... affecting about 7 percent of the population. That,s an ...
... N.C., March 21 A CI head once noted ... it, but the only,time you realize you need it ... today,s marketing space, most companies need competitive,intelligence to effectively ... key insights are lacking that people begin to realize ...
... are small, the trend is worrisome, study says ... small, but worrisome number of facelift patients became ... MRSA, a new study reports. , About one ... developed the so-called "superbug" methicillin-resistant Staphylococcus aureus ...
... and genetic testing, study shows , , FRIDAY, March ... discuss a family,s cancer history has a major impact ... women at moderate risk for breast cancer, according to ... black women are less likely than white women ...
Cached Medicine News:Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Poison Prevention Tips to Protect the Most Vulnerable 2Health News:Diabetes' Toll Continues to Grow 2Health News:Diabetes' Toll Continues to Grow 3Health News:Diabetes' Toll Continues to Grow 4Health News:New Research Uncovers How to Build and Maintain an Effective Competitive Intelligence Group 2Health News:Some Facelift Patients Infected With MRSA 'Superbug' 2Health News:Some Facelift Patients Infected With MRSA 'Superbug' 3Health News:Family Discussion Plays Role in Breast Cancer Awareness 2
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... Nerve Electrodes provide direct cranial nerve ... patented circumferential design provides sensitive contact ... stable real-time recordings. This unique approach ... the removal of acoustic neuromas, microvascular ...
... Ad-Techs Model CMU Cortical Mapping Unit ... of recording EEGs from exposed cortex during ... each electrode plate can be positioned independently ... clamp provides two alternative mounting locations and ...
An ambulatory recorder can help the patient be more comfortable and at ease as well as increasing an EEG laboratory's recording capacity....
Medicine Products: